Trials / Unknown
UnknownNCT05070598
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
A Prospective, Single-arm, Phase II Study of Camrelizumab Combined With Pyrotinib Maleate, Nab-paclitaxel and Tegafur Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Shengjing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur | Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle |
Timeline
- Start date
- 2021-09-07
- Primary completion
- 2023-09-01
- Completion
- 2024-03-30
- First posted
- 2021-10-07
- Last updated
- 2021-10-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05070598. Inclusion in this directory is not an endorsement.